Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

Wei Zhou1,2, Adrian Lim1, Mouad Edderkaoui1, Arsen Osipov1, Heshui Wu2, Qiang Wang1, Stephen Pandol1

1. Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
2. Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Corresponding author: Dr. Wei Zhou; PDIZhou@hust.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

Although recent advances in cancer treatment significantly improved the prognosis of patients, drug resistance remains a major challenge. Targeting programmed cell death is a major approach of antitumor drug development. Deregulation of programmed cell death (PCD) contributes to resistance to a variety of cancer therapeutics. Yes-associated protein (YAP) and its paralog TAZ, the main downstream effectors of the Hippo pathway, are aberrantly activated in a variety of human malignancies. The Hippo-YAP pathway, which was originally identified in Drosophila, is well conserved in humans and plays a defining role in regulation of cell fate, tissue growth and regeneration. Activation of YAP signaling has emerged as a key mechanism involved in promoting cancer cell proliferation, metastasis, and drug resistance. Understanding the role of YAP/TAZ signaling network in PCD and drug resistance could facilitate the development of effective strategies for cancer therapeutics.

Keywords: Programmed cell death, YAP/TAZ, Apoptosis, Ferroptosis, Autophagy, Drug resistance

Current landscape of cancer therapy and challenge

Surgery combined with chemotherapy or radiotherapy are currently the first-line treatment modalities for localized tumors. However, many patients suffer from tumor recurrence and development of acquired resistance despite success in initial treatment [1, 2]. Most patients with advanced solid tumors, such as hepatocellular carcinoma, pancreatic adenocarcinoma and glioblastoma, show intrinsic resistance to chemotherapy and other antitumor agents at the initial stage [3-5]. Drug resistance in cancer is multifaceted and can be mediated by mechanisms that impact on drug availability, cell proliferation and response to DNA damage or metabolic pathways. Deregulation of cell death signaling represents an important mechanism of drug resistance because most of the anti-tumor therapy agents aim to trigger programmed cell death [6]. Thus, understanding the signaling pathways involved in regulating PCD and drug resistance can provide insights into development of new therapeutic targets.

The Hippo-YAP signaling pathway

The Hippo-YAP signaling plays an important role in aspects of malignant transformation, including cell proliferation, tumor progression, metastasis, and drug resistance [7-10]. YAP and its paralog TAZ are the main downstream effectors of the Hippo-YAP pathway and act as a transcriptional coactivator [11-13]. The YAP signaling can translocate into the nucleus and mediates gene transcription by binding to transcription factors, such as the TEA domain family (TEAD) proteins [12]. YAP exhibits oncogenic activities [14, 15] and is upregulated in most solid tumors [16-22]. YAP signaling target genes participate in regulation of development, cell proliferation, migration and survival [23-27].

YAP signaling is responsive to intercellular
adhesion, cell density, and mechanical stiffness of the extracellular matrix [7-10]. YAP can be negatively regulated by a cascade of phosphorylation events that are mediated by mammalian Ste20-like kinases1/2 (MST1/2, the mammalian homolog of Hippo) and large tumor suppressor 1/2 (LATS1/2) [11, 28, 29]. The scaffold proteins of adherens junctions, such as NF2 or KIBRA/WWC1, can recruit MST and LATS kinases to the plasma membrane and mediates their activation [30-33]. The kinase activity of MST1/2 can be activated by binding to the Salvador Family WW Domain Containing Protein 1 (SAV1), a scaffold protein that also forms a complex with LATS1/2[11, 28, 29, 34]. The Ras Association Domain Family Members (RASSFs) can also associate with MST1 and enhance its kinase activity [35-37]. MST1/2 subsequently activates LATS1/2 by phosphorylating LATS1/2 and its regulatory protein Mps one binder kinase activator-1 (MOB-1) [38, 39]. In parallel to MST1/2, the MAP4K family kinases can also phosphorylate and activate LATS1/2 [40-42]. The activated LATS1/2 then phosphorylates YAP/TAZ [43, 44]. The phosphorylated YAP can associate with the 14-3-3 proteins and is rendered transcriptionally inactive due to retention in the cytoplasm [45, 46]. Alternatively, the phosphorylated forms of the YAP/TAZ proteins can also be primed for β-TrCP-mediated ubiquitination and degradation [13, 43, 47]. In addition, YAP can be inactivated by binding to a series of proteins, such as angiomotin, Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14) and tight junction protein zonula occludens [48-51]. Conversely, YAP can be activated by G-protein coupled receptors or the mevalonate pathway through rho GTPase signaling [52-55]. Epithelial cell transforming 2 (ECT2), a guanine nucleotide exchange factor for Rho-like GTPases that activates Rho signaling, can positively regulate YAP function and is reciprocally regulated by YAP [56]. The SRC family tyrosine kinases and the c-ABL kinase have also been reported to promote YAP signaling by tyrosine phosphorylation of YAP [57-59].

**Figure 1. Hippo-YAP pathway signaling and function.** YAP signaling is negatively regulated through a cascade of phosphorylation events mediated by MST1/2 and LATS1/2, which leads to phosphorylation of YAP and subsequent proteasomal degradation or retention in the cytoplasm. Alternatively, YAP can be inactivated by binding to angiomotin, PTPN14 and zonula occludens. Signaling events triggered by GPCR and Rho can activate YAP by inducing its nuclear translocation. YAP target genes are involved in aspects of organ development, regeneration, and malignant transformation.
In addition to phosphorylation, YAP signaling can be regulated by other forms of post-transcriptional modifications. For example, YAP can be methylated by the SET Domain Containing 1A (SET1A) methyltransferase complex, which promotes its oncogenic activities by blocking nuclear export [60]. YAP can also be modified by O-GlcNAcylation that prevents its phosphorylation by LATS1, leading to nuclear localization and enhanced tumorigenic functions [61]. Moreover, O-GlcNAcylation of LAST2 has been reported to cause YAP/TAZ activation and promote tumor growth [62]. Acetylation of LAST1 inhibits YAP phosphorylation and degradation and promotes cancer cell invasion and growth [63]. Thus, post-transcriptional modification is an important mechanism in regulating YAP signaling.

YAP signaling activation and Drug Resistance

A growing number of studies reveal that activation of YAP signaling contributes to resistance to chemotherapy, targeted therapy and immunotherapy.

(1) YAP signaling and Chemotherapy

DNA-damaging agents, such as doxorubicin, irinotecan, oxaliplatin, and cisplatin, aim at DNA replication as a target to induce cytotoxic effects and are widely used in the clinics. YAP signaling is closely linked to the resistance of DNA-damaging agents. YAP is a key regulator of doxorubicin resistance in thyroid cancer and is regulated by tripartite motif-containing protein 11 (TRIM11) [64]. Overexpression of YAP confers resistance to doxorubicin by regulating bcl-xl [65]. Activation of YAP also promotes doxorubicin chemoresistance in cholangiocarcinoma and osteosarcoma cells [20, 66]. Inhibition of YAP enhances oxaliplatin and irinotecan sensitivity [67, 68]. YAP activation induces cisplatin resistance in small cell lung cancer (SCLC) cells [69], whereas knockdown of YAP increases the sensitivity of cisplatin in ovarian cancer cells [48, 70]. In addition, overexpression of TAZ is involved in regulation of cisplatin resistance of cervical, gastric, lung and ovarian cancer [22, 71-73].

Agents inhibiting metabolic pathways represent another major class of chemotherapy agents that can sabotage DNA or RNA synthesis and inhibit cell division and survival. Gemcitabine and 5-fluorouracil (5-FU) are cytidine and uracil nucleoside analogues, respectively, which are widely used for the treatment of multiple tumors. Knockdown of YAP enhances gemcitabine sensitivity [74]. In addition, high levels of YAP are associated with poor survival in patients following 5-FU treatment, which is accompanied with an increase of M2 polarization of macrophage in the tumor [75]. However, a recent study reported that overexpression of an activating mutant form of YAP appears to enhance cancer cell sensitivity to gemcitabine and 5-FU, by reducing drug efflux [76]. It should be noted that these findings remain to be corroborated with knockdown studies.

Anti-microtubule agents block mitosis by interfering with microtubules dynamics and induce apoptosis. Examples of classical anti-microtubule agents include taxanes (paclitaxel and docetaxel), which are widely used for the treatment of breast, ovarian, gastric, pancreatic and colorectal cancer [77]. YAP has been reported to confer resistance to paclitaxel in cancer cells [78, 79]. Similarly, TAZ and TAZ/TEAD-mediated expression of Cyr61 and CTGF are also vital in paclitaxel response [21, 80]. Moreover, down-regulation of YAP has been found to enhance sensitivity to docetaxel [81]. The mechanism by which YAP signaling modulates resistance to taxanes may involve YAP- and TEAD-regulated expression of ATP Binding Cassette Subfamily B Member 1 (ABCB1), which encodes the multidrug resistance protein 1 and is implicated in paclitaxel resistance [82]. In addition, YAP mediates the expression of an array of mitotic genes and deregulation YAP signaling can lead to aberrant mitotic checkpoint control [83, 84]. The mitotic regulator cyclin-dependent kinase 1 (CDK1) phosphorylates YAP in response to paclitaxel-induced G2/M arrest [85]. But its role in drug resistance remains to be clarified.

Thus, an increasing body of evidence indicate that activation of YAP signaling results in chemoresistance and inhibition of this pathway may enhance cancer cell sensitivity to chemotherapeutic drugs. Targeting YAP signaling pathway represents a potential strategy to overcome chemotherapy resistance. Indeed, the combination of YAP inhibitor with chemotherapy has shown increased efficacy in chemoresistant tumors [86, 87].

(2) YAP signaling and Targeted Therapy

Targeted therapy is designed to block molecules and pathways that are vital for cancer cell proliferation, survival, invasion and metastasis and rewrote the paradigm of leukemia treatment [88]. Targeted therapy for epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2), vascular endothelial growth factor receptor (VEGFR), and BRAF have been developed for clinical use [88]. In this section, we will briefly discuss how YAP signaling regulates targeted therapies.
Figure 2. YAP signaling and chemotherapy. YAP/TAZ-mediated tumor chemoresistance by increasing survival in DNA damage and cell cycle arrest and reducing drug efflux. Anti-microtubule chemotherapeutic agents can induce G2/M cell cycle blockade. YAP signaling regulates their resistance through pathways such as CTGF/Cyr61, ABCB1, and CDKs. YAP signaling modulates resistance to DNA damage agents through TRIM11, p53, IL-8 pathways. Gemcitabine and 5-FU affect DNA and RNA synthesis in tumor cells. YAP signaling regulates their resistance through M2 polarization.

BRAF, a serine/threonine protein kinase of the RAF kinase family, is a key regulator of the MAP kinase signal transduction pathway. BRAF gene mutations occur in a large percentage of cancers, including approximately 50% of melanomas, 20% to 40% of thyroid cancers, and 10% of colorectal cancers [89]. Although BRAF inhibitors have shown benefit in melanoma patients with the oncogenic BRAFV600E mutant, acquired drug resistance remains a significant obstacle [90]. NF-2, a negative regulator of YAP signaling, was identified as a gene associated with cancer cell sensitivity to BRAF inhibitor, which indicates that YAP signaling could participate in BRAF inhibitor resistance [91]. In a separate study, activation of YAP was shown to induce resistance to BRAF inhibitor in melanoma cells through the actin dynamic regulator testis associated actin remodeling kinase 1 (TESK1) [92]. In addition, YAP confers immune evasion in BRAF inhibitor resistant melanoma cells by promoting PD-L1 expression, which can be targeted by immune checkpoint therapy [93]. This finding suggests that the combination of BRAF inhibitor with immunotherapy may represent a viable approach to treat BRAF inhibitor resistant melanoma.

EGFR is a receptor tyrosine kinase that is frequently mutated in many tumors [94]. Small-molecule tyrosine kinase inhibitors (TKIs) for EGFR have shown efficacy in treatment of EGFR-mutated tumors [95]. However, resistance remains a problem for clinicians. Numerous studies have indicated that activation of YAP/TAZ is widely associated with in EGFR TKI resistance [96-98]. YAP regulates epithelial-to-mesenchymal transition (EMT)-induced resistance to EGFR TKI in non-small cell lung cancer (NSCLC) via FOXM1/SAC pathway [99]. YAP could also mediate EGFR TKI-resistant through upregulation of AXL receptor tyrosine kinase [100] or the autophagy mediator p62 [101]. Combination of YAP inhibitor and EGFR TKI improved response in EGFR inhibitor resistant NSCLC [102].

YAP signaling is also implicated in resistance to targeted therapies for HER-2, MEK, RAS, ALK and BET inhibitors. YAP1 dephosphorylation and TAZ overexpression are closely related to trastuzumab resistance by regulating cytokines like CCL5 in HER-2 positive breast cancer cell lines [103]. YAP deletion sensitizes the MEK inhibitor trametinib by depletion of MYC/MYCN and E2F transcriptional output in neuroblastoma cells [104]. Dasatinib can enhance the antitumor effect of trametinib in KRAS-mutant cancer models by inhibiting the expression of TAZ protein [105]. YAP activation promotes resistance to ALK-TKI through induction of p21 expression [106]. TAZ nuclear localization and transcriptional activity induces resistance to inhibitors of BET family proteins [107]. In summary, activation of YAP/TAZ signaling
contributes to the resistance to an array of targeted therapy agents in various tumors. Targeting YAP signaling may improve the outcomes of targeted therapy.

(3) YAP signaling and Immunotherapy

The recent success of using immune checkpoint inhibitors for the treatment of certain human cancers represents a breakthrough in immunotherapy. Immune checkpoint receptors play a critical role in the maintenance of immune homeostasis. The classic immune checkpoint receptors include PD-1, CTLA-4, and TIGIT. The engagement of the immune checkpoint receptors can result in anergy of CD8+ T cells and enhance tumorigenesis and invasiveness of tumors. Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor-reactive T cells to mount an effective antitumor response [108, 109]. The anti-PD-1/PD-L1 agents, the most commonly used immune checkpoint inhibitors, has shown promising outcomes in the treatment of certain cancer types, significantly extending the overall survival of patients [110]. Monoclonal antibodies against PD-1/PD-L1 or CTLA-4 have shown promising efficacy in certain tumors [111-113]. Emerging evidence indicates an important role for YAP signaling in modulating anti-PD-1/PD-L1 immunotherapy. PD-L1 is a direct transcriptional target of YAP signaling, knockdown of YAP inhibits expression of PD-L1 and reverses resistance to EGFR-TKI [114]. TAZ also upregulates PD-L1 expression in pancreatic cancer, leading to immune evasion and immunotherapy resistance [115]. Activation of YAP-mediated transcriptional hubs in the nuclei is associated with resistance of anti-PD-1 in a mouse model of lung cancer cells, and inhibition of YAP can enhance the efficacy of anti-PD-1 therapy [116]. In addition, YAP signaling in cancer cells can facilitate recruitment of macrophages or myeloid-derived suppressor cells (MDSC) to the tumor microenvironment by regulating CXCL5, IL-6 and Csf1-3, and inhibition of YAP-mediated immune cell infiltration impairs tumor growth [117, 118]. These findings indicate that targeting YAP signaling may improve the efficacy of immunotherapy.

YAP signaling and Programmed Cell Death

Apoptosis, ferroptosis and other forms of PCD are associated with cancer drug resistance [119, 120]. Recent studies discovered that YAP signaling plays an important role in the regulation of PCD in cancer [121]. Understanding the relationship between YAP signaling and PCD can assist the development of more effective cancer therapeutic strategies.

Figure 3. YAP signaling and targeted therapy. YAP signaling drives resistance of BRAF inhibitors by regulating TESK1. YAP signaling mediates EGFR TKI resistance by via FOXM1/p62. YAP signaling mediates Trastuzumab, ALK TKI and MEK inhibitors resistance by via CCL5, EGFR/AXL and MYC/E2F, respectively.
Figure 4. YAP signaling and immunotherapy. YAP mediates immunotherapeutic resistance by regulating cytotoxic T cells through upregulation of PD-L1 expression in cancer cells. YAP-mediated transcription of CXCL5, IL-6 and Csf1-3 promotes MDSC recruitment and macrophage infiltration.

YAP signaling and Apoptosis

Apoptosis is a major cancer cell response to most therapeutic drugs. Dysregulation of apoptosis contributes to tumorigenesis and drug resistance [119]. YAP signaling participates in the regulation of apoptosis and inhibition of YAP signaling can promote apoptosis via multiple pathways. Inhibition of YAP signaling can promote apoptosis in multiple pathways. Knockdown of YAP and TAZ can enhance apoptosis under hypoxic condition [122]. YAP appears to modulate cancer cell susceptibility to apoptosis triggered by an ER stress inducing agent [123]. Knockdown of YAP can sensitize colon cancer cells to inhibitors of the MAPK pathway, which may involve YAP-mediated expression of CDK6 [124]. YAP is implicated in playing a role in determining the switch between apoptotic and survival pathways following activation of G protein–coupled bile acid receptor (GPBAR) signaling [125]. Inhibition of YAP increases cancer cell apoptosis induced by genotoxic agents [126]. Knockdown of YAP enhances apoptosis in cancer cells treated with the Abl and Src family kinase inhibitor bosutinib, which is associated with mitochondrial fragmentation and reactive oxygen species (ROS) accumulation [127]. Indeed, knockdown of YAP increases mitochondrial fission via JNK-Drp1, which can lead to apoptosis [128].

Activation of YAP can inhibit apoptosis by mediating the pro-apoptotic function of nuclear receptor 4A1 (NR4A1) [129]. Knockdown of YAP in cancer cells increases the levels of ER stress and apoptosis [18]. Ras association domain family member 4 (RASSF4) enhances apoptosis by decreasing YAP-regulated bcl-2 expression [130]. Knockdown of YAP can induce apoptosis by reducing SIRT1- and Mfn2-mediated mitophagy [131]. The YAP/TEAD4 complex can inhibit apoptosis and promote cancer progression by activating kinesin family member 4A (KIF4A) expression [132]. Overexpression of YAP promotes proliferation and suppress apoptosis via increase of bcl-2 [133]. YAP knockdown sensitizes bladder cancer cells to cisplatin-induced apoptosis, which is accompanied with downregulation of surviving [134]. A recent study showed that YAP plays a vital role in evasion of apoptosis by mediating cancer cell dormancy, which involves recruitment of the EMT transcriptional factor SLUG and suppression of the expression of the pro-apoptotic protein bcl-2-modifying factor (BMF) [135].

Further investigation of the precise mechanisms regarding the regulation of apoptosis by YAP signaling may contribute to the discovery of potential therapeutic targets.

YAP signaling and Ferroptosis

Ferroptosis is a biochemically and morphologically distinct form of PCD characterized by iron-dependent lipid peroxidation and compromise of
cell membrane integrity [136]. Lipid peroxidation is a process under which oxidants such as free radicals and intracellular ROS attack lipids especially polyunsaturated fatty acids, leads to lipid peroxidation and cell death. Imbalance of iron redox ability leads to the production of oxygen free radicals and damages various cellular components, eventually induces ferroptosis. Cancer cells have developed many defense mechanisms to prevent lipid peroxidation. The most well-known is the glutathione peroxidase 4 (GPX4)-glutathione (GSH) system. GPX4 can reduce peroxidized lipids to their corresponding alcohols by binding to its cofactor GSH [137]. Ferroptosis is associated with multiple diseases, such as cancer, inflammation, heart injury and sepsis [138-141]. A growing number of studies indicates that YAP signaling modulates ferroptosis by regulating expression of genes involved in keeping the balance of intracellular ROS and lipid peroxidation.

YAP can modulate iron concentration through the transcriptional regulation of transferrin receptor (TFRC) [142]. Activation of YAP also confers sensitivity to ferroptosis via regulation of the arachidonate lipoxygenase 3 (ALOXE3) [143], which promotes lipid peroxidation and ferroptosis [144], or by upregulating multiple regulators of ferroptosis, particularly TRFC and acyl-CoA synthetase long chain family member 4 (ACSL4) [145]. TAZ mediates ferroptosis through indirectly regulating the expression of the ROS-generating nicotinamide adenine dinucleotide phosphate oxidases (NOX) through angiopoietin-like 4 (ANGPLT4)-NOX2 and epithelial membrane protein 1 (EMP1)-NOX4 axis [146, 147]. YAP/p53 axis is required for lipid peroxidation and ferroptosis induced by cytoglobin, a heme-binding protein that mediates redox homeostasis in cells [148].

However, in a separate line of studies, YAP appears to have anti-ferroptosis effect. YAP/TAZ mediate the expression of solute carrier family 7 member 11 (SLC7A11), a subunit of the cystine/glutamate transporter that is important for maintaining intracellular cysteine and glutathione storage, and thus contributes to resistance to ferroptosis [149, 150]. Induction of ferroptosis by inhibition of the cystine/glutamate transporter system by erastin is accompanied with glutamate-induced O-GlcNAcylation and down regulation of YAP, and ectopic expression of a mutant form of YAP that cannot undergo O-GlcNAcylation reduces sensitivity to ferroptosis [151]. Moreover, YAP can also protect cells from ferroptosis by suppressing the expression of ferritin light chain, a major protein important for storing intracellular iron [152].

In summary, YAP signaling can regulate genes involved in different aspects of lipid peroxidation. The overall effect of YAP disruption on ferroptosis may depends on the genetic background of the cell types or the metabolic environment.

---

**Figure 5. YAP signaling in regulation of apoptosis.** YAP signaling can regulate apoptosis by modulating (1) Mitochondria-related events (e.g. bcl-2, BMF, NR4A1, SIRT1/Mfn2, survivin and JNK/Drp1); (2) ROS and ER stress responses; or (3) Mediators of the cell cycle, (e.g. CDK6 and survivin).
YAP signaling and Autophagy

Autophagy is a mechanism by which cells adapt to physiological or pathological changes by degrading and recycling parts of the cell in a lysosome-dependent manner. Autophagy is vital in maintaining organismal homeostasis [153, 154] and dysfunction of autophagy is implicated in multiple diseases [155-157]. The molecular mechanism of autophagy involves several autophagy-associated proteins (ATG). Various stimuli, such as nutrient deficiencies and hypoxia, can leads to the formation of phagocytic vesicles, a step regulated by two protein complexes. One is the Vps34 complex containing Vps34, ATG6, ATG14 and Vps15. The other is the unc-51 like autophagy activating kinase (ULK1)/ATG1 complex, which is an important positive regulator of autophagosome formation [158]. Autophagy is involved in aspects of tumorigenesis, including cancer cell survival, invasion and immune response [159-162]. Recent studies have shown complex interactions between YAP signaling and autophagic pathways [163].

YAP signaling promotes autophagy in most tumors. YAP is required for IncRNA-ATB induced autophagy [164]. YAP activates autophagy by promoting ATG5 transcription, while autophagy in turn negatively regulates YAP through autophagic degradation [165]. Disruption of autophagy by genetic deletion of ATG7 in the hepatocytes leads to upregulation of YAP and malignant transformation in the liver, which can be reversed by concurrent deletion of YAP [166]. Silencing of YAP leads to impaired autophagy, which enhances cisplatin sensitivity in cancer cells [70]. Proto-oncogene SKIL could induce TAZ-dependent autophagy in NSCLC cell lines [167]. Cisplatin-induced autophagy can activate YAP by decreasing phosphorylation [168]. YAP promotes autophagy and tumor progression in glioblastoma through upregulation of high mobility...
Contrary to the above-mentioned studies, YAP signaling has also been shown to inhibit autophagy. YAP can suppress autophagy in sarcoma [169]. Autophagy induced by depletion of TAZ could inhibit migration and invasion [170]. Blockade of YAP induces autophagy-related cell death and confers sensitivity of chemotherapy [19]. YAP inhibits autophagy through the suppression of phosphatase and tensin homolog (PTEN) and activation of the AKT/mTOR pathway [171]. Moreover, YAP inhibits autophagy by upregulating expression of bcl-2 [172].

In summary, YAP signaling appears to play opposing roles in regulation of autophagy, which may be dependent on the genetic background of the tumor. The mechanisms involving in the relationship between YAP signaling and autophagy needs further exploration.

**YAP signaling and Pyroptosis**

Pyroptosis, also known as inflammatory necrosis, is a type of PCD characterized by Gasdermin-mediated membrane rupture and release of inflammatory molecules [173]. Pyroptosis is usually initiated in response to viral and bacterial infections, accompanied by activation of the inflammasome and secretion of pro-inflammatory cytokines [174]. Pyroptosis facilitates inflammatory microenvironment, which promotes carcinogenesis and metastasis [175]. The role of pyroptosis in tumor development is complicated. In the initiation stage, pyroptosis can promote tumor development through inflammasome or the release of pro-inflammatory cytokines, such as interleukin-1β and IL-18 [176, 177]. In later stages, the inhibition of pyroptosis may promote tumor progression [178].

Pyroptosis is involved in the regulation of drug resistance in cancer. Downregulation of Gasdermin E (GSDME), a key regulator of pyroptosis, confers retinoblastoma cells resistance to chemotherapy [179]. Bioinformatics analysis reveals that four regulatory genes of pyroptosis are closely related to temozolomide resistance in glioma [180]. Caspase-1/GSDMD dependent pyroptosis is involved in cisplatin resistance of NSCLC cells [181]. Pyroptosis induced by STAT-3β enhances cisplatin sensitivity in esophageal squamous carcinoma cells [182]. In addition, pyroptosis-related gene signature has shown promise in predicting the efficacy of immunotherapy in multiple cancer types [183]. Pyroptosis improves the sensitivity of immunotherapy by remodeling tumor microenvironment [184].

Existing research regarding YAP signaling on the regulation of pyroptosis is mostly focused on non-cancerous diseases like infection, inflammation and diabetes [185-187] and only a few studies explored the role of YAP signaling in cancerous pyroptosis. Inactivation of YAP switch chemotherapy induced cell death from apoptosis to pyroptosis through upregulating the expression of GSDME [69]. A recent study showed that MST1 can promote ROS-induced pyroptosis, which is accompanied by inactivation of YAP via phosphorylation and results in suppression of tumor cell proliferation and invasion [188].

*Figure 7. Connection between YAP signaling and Autophagy. LncRNA ATB and SKIL can promote autophagy via YAP signaling. YAP signaling promotes autophagy through regulation of HMGB1, ATG5. On the other hand, YAP signaling inhibits autophagy via bcl-2, and PTEN/AKT pathway. YAP signaling could regulate carcinogenesis and chemosensitivity via autophagy.*
Conclusion and Future Perspectives

In summary, YAP signaling is engaged in the regulation of multiple forms of programmed cell death, including apoptosis, ferroptosis, autophagy, and pyroptosis. Activation of YAP/TAZ contributes to resistance to a variety of tumor therapeutic modalities, such as chemotherapy, targeted therapy and immunotherapy. Verteporfin (VP), originally used for treating fundus macular degeneration, possesses potency of effectively YAP inhibition [189]. Several studies indicate that VP could increase sensitivity to targeted or chemotherapy drugs by inhibition of YAP [190-194]. Clinical trials using VP for the treatment of pancreatic cancer are underway [195]. As such, VP has the potential to become an anti-tumor agent of multiple tumor types in the future. More recently, a pan-TEAD inhibitor has been developed and showed activity in blocking YAP signaling and overcoming KRAS G12C inhibitor resistance [196]. Moreover, small molecule inhibitors of TEAD auto-palmitoylation have also been reported to exhibit potency to inhibit NF2-deficient Mesothelioma [197]. Similarly, K-975, a TEAD inhibitor, can inhibit the proliferation of malignant pleural mesothelioma (MPM) cell lines and provide significant survival benefit in MPM xenograft model [198]. In addition, several other YAP/TEAD inhibitors are currently tested in the preclinical and clinical research stages, and may provide more drug choices for YAP/TEAD based anti-tumor therapy in the future [199]. The advancement of our understanding in YAP or YAP-mediated signaling events in cancer drug resistance may lead to development of new therapeutic regimen for cancer.

Abbreviations

PCD: programmed cell death; YAP: yes-associated protein; TEAD: TEA domain family; MST: mammalian Ste20-like kinases; LATS: large tumor suppressor; MOB-1: Mps one binder kinase activator-1; KIBRA: Kidney and Brain expressed protein; WWCI: WW and C2 domain containing 1; GPCR: G-protein coupled receptors; PTPN14: protein tyrosine phosphatase non-receptor type 14; SET1A: set domain containing 1A; HCC: hepatocellular carcinoma; SCLC: small cell lung cancer; HIF: hypoxia-inducible factor; TRIM11: tripartite motif-containing protein 11; CTGF: connective tissue growth factor; ABCB1: ATP binding cassette subfamily B member 1; CYR61: cysteine-rich angiogenic inducer 61; CDK: cyclin-dependent kinase; COX-2: cyclooxygenase 2; 5-FU: 5-fluorouracil; RAR: retinoic acid receptors; RXR: retinoid X receptors; ALDH1A3: aldehyde dehydrogenase 1 family member A3; OCT4: octamer-binding transcription factor 4; EGFR: epidermal growth factor receptor; HER-2: human epidermal growth factor receptor 2; VEGFR: vascular endothelial growth factor receptor; TESK1: testis associated actin remodeling Kinase 1; TKI: tyrosine kinase inhibitor; EMT: epithelial-to-mesenchymal transition; NSCLC: non-small cell lung cancer; FOXM1: forkhead box protein M1; SAC: saccin molecular chaperone; MEK: mitogen-activated protein kinase kinase; BET: bromodomain and extra-terminal motif; PD-1: Programmed death protein 1; PD-L1: programmed cell death ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated antigen 4; TIGIT: T cell immunoglobulin and ITIM domain; MDSC: myeloid-derived suppressor cells; IL-6: Interleukin 6; CSF: colony stimulating factor; CXCL5: c-c motif chemokine ligand 5; ER: endoplasmic reticulum; PERK: protein kinase RNA-like ER kinase; EIF2a: eukaryotic translation initiation factor 2A; MAPK: mitogen-activated protein kinase; GPBAR: G protein-coupled bile acid receptor; JNK: c-Jun n-terminal kinase; NR4A1: nuclear receptor 4A1; KIF4A: kinesin family member 4A; BMF: Bcl-2-modifying factor; GPX4: glutathione peroxidase 4; GSH: glutathione; TFRC: transferrin receptor; ACSL4: acyl-CoA synthetase long chain family member 4; NOX: nicotinamide adenine dinucleotide phosphate oxidases; SLC7A11: solute carrier family 7 member 11; ALOXE3: Arachidonate Lipoxygenase 3; SUFU: suppressor of fused homolog; ANGPLT4: angiopoietin-like 4; UPR: unfolded protein response; RAC1: Rac family small GTPase 1; ATG: autophagy-associated proteins; ULK1: unc-51 like autophagy activating kinase; TNBC: triple-negative breast cancer; ANKR1D1: ankyrin repeat domain 1; ERK: extracellular signal-regulated kinase; HMGBl: high mobility group box 1; UPR: unfolded protein response; RAC1: Rac family small GTPase 1; mTOR: mechanistic target of rapamycin kinase; PTEN: phosphatase and tensin homolog; GSDME: gasdermin E; MST1: macrophage stimulating 1; VP: verteporfin.

Acknowledgments

All figures were created with BioRender.com.

Author Contributions

Wei Zhou and Qiang Wang initiated and drafted the manuscript. Adrian Lim participated in collecting related studies. Heshui Wu, Mouad Edderkaoui and Arsen Osipov participated in the design of the review. Stephen Pandol revised the manuscript. All authors have read and agreed on the published version of the manuscript.
**Competing Interests**

The authors have declared that no competing interest exists.


